NOVO-DIFLUNISAL DIN 02048507
Health Canada record
| Active ingredient(s) | DIFLUNISAL 500 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N02BA11 DIFLUNISAL |
| Original market date | 31-Dec-1993 |
| Current status date | 30-Apr-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DIFLUNISAL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02039486 | DIFLUNISAL | AA PHARMA INC | Tablet | DIFLUNISAL 250 MG | Dormant |
| 02039494 | DIFLUNISAL | AA PHARMA INC | Tablet | DIFLUNISAL 500 MG | Dormant |
| 02130904 | DIFLUNISAL-250 - TAB 250MG | PRO DOC LIMITEE | Tablet | DIFLUNISAL 250 MG | Cancelled Post Market |
| 02130912 | DIFLUNISAL-500 - TAB 500MG | PRO DOC LIMITEE | Tablet | DIFLUNISAL 500 MG | Cancelled Post Market |
| 00587699 | DOLOBID TAB 250MG | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Tablet | DIFLUNISAL 250 MG | Cancelled Post Market |
| 00576131 | DOLOBID TAB 500MG | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Tablet | DIFLUNISAL 500 MG | Cancelled Post Market |
| 02048493 | NOVO-DIFLUNISAL | TEVA CANADA LIMITED | Tablet | DIFLUNISAL 250 MG | Cancelled Post Market |
| 02058405 | NU-DIFLUNISAL TAB 250MG | NU-PHARM INC | Tablet | DIFLUNISAL 250 MG | Cancelled Post Market |
| 02058413 | NU-DIFLUNISAL TAB 500MG | NU-PHARM INC | Tablet | DIFLUNISAL 500 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15739 | 2014-06-20 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 436 | 2002-07-16 | New Drug Submission (NDS) | ALTERNATE FORMULATION, MANUFACTURING PROCEDURE AND MANUFACTURING SITE |
International API supply for DIFLUNISAL
4 active FDA Drug Master Files.
Request a quote for NOVO-DIFLUNISAL